Search alternatives:
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
n decrease » nn decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
50 n » 50 ns (Expand Search), 50 ng (Expand Search), 50 μ (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
n decrease » nn decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
50 n » 50 ns (Expand Search), 50 ng (Expand Search), 50 μ (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50.
Published 2024“…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”
-
7
-
8
Body and absolute and relative organ weights of rats post PM2.5 exposure (‾χ±s, n = 8).
Published 2025Subjects: -
9
Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration.
Published 2025“…<b>(B)</b> A significant decrease in the proliferative clonal capacity of U251MG colonies was observed with 50ΜM and 100ΜM SHG-44 treatment. …”
-
10
-
11
-
12
Exposure to low CO<sub>2</sub> levels decreases ER cholesterol levels.
Published 2023“…<b>(B)</b> Bioluminescence recordings from the different conditions as depicted in <b>(A)</b>, the arrow indicates the time CO<sub>2</sub> was shifted from 5% to 1% (mean ± SE, <i>n</i> = 4 biological replicates per condition, AUC for 0 mM 0.34 ± 0.007, 1.59 ± 0.004 (<i>P</i> < 0.0001), 0.5 mM 1.00 ± 0.023, 2.68 ± 0.04 (<i>P</i> < 0.0001), 1 mM 1.66 ± 0.07, 3.34 ± 0.04 (<i>P</i> < 0.0001), 3 mM 2.06 ± 0.02, 2.79 ± 0.07 (<i>P</i> < 0.0001), 5 mM 2.02 ± 0.05, 2.43 ± 0.06 (<i>P</i> < 0.002), 7 mM 1.85 ± 0.01, 1.77 ± 0.02 (<i>P</i> < 0.02) two-sided Student’s <i>t</i> test). …”
-
13
-
14
-
15
Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to...
Published 2022“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
-
16
Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to...
Published 2022“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
-
17
-
18
-
19
-
20